undamentalytics Newsletter
Sign in

ANI Pharmaceuticals Inc balance sheet

At the end of fiscal 2025, ANI Pharmaceuticals Inc had total assets of $1.44bn, total liabilities of $900m and shareholders' equity of $541m. It held $286m in cash against $309m of debt.

Balance sheet

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2009Dec 20092010Dec 20102011Dec 20112012Dec 20122013Dec 20132014Dec 20142015Dec 20152016Dec 20162017Dec 20172018Dec 20182019Dec 20192020Dec 20202021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMJun 2026
Cash and equivalents3038001116915527314362810048221145286360
Receivables———51317224659657296129165162222281274
Inventory———34813263841486182105111137143143
Total current assets—4158928195193103132153188170322344520528753825
Goodwill———022222444282828606262
Total assets—456214452602853234124314574617727609041,2841,4401,494
Accounts payable—5321323491511232937466374
Deferred revenue (current)———————00100000———
Total current liabilities—87841312323916662798899145194278284
Short-term debt———8———033101311191721
Long-term debt—1717——10711307067176172287286285309292280
Total debt0191780107113144144180186186287287286318309301
Total liabilities—2625114120125153237233244265413422447856900897
Shareholders' equity1619−34−4341140160170175197213196334314433404541597
Non-controlling interests and other (assets − liabilities − equity)——7246————————252525———
Shares outstanding———————————————21m22m—

Balances at each fiscal year end (quarter end in the quarterly view). Total debt is short- plus long-term borrowings, including lease debt where the company reports it within debt. Where assets do not equal liabilities plus shareholders' equity, the difference (non-controlling interests, redeemable preferred shares) is shown on its own line.

Compare with peers

Head to head: ANIP vs HRMYANIP vs PBHANIP vs AXSMANIP vs TRLV

More: Pharmaceuticals stocks compared, Health Care sector, rankings of US companies

Figures from ANI Pharmaceuticals Inc's SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to ANI Pharmaceuticals Inc.